Lamotrigine
Adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic..., Conversion to monotherapy in adults (aged 16 years and older) with partial-onset..., Maintenance treatment of bipolar I disorder to delay mood episodes
Boxed warning
- WARNING: SERIOUS SKIN RASHES Lamotrigine can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (aged 2 to 17 years) and 0.08% to 0.3% in adults receiving lamotrigine. One rash-related death was reported in a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking lamotrigine as adjunctive therapy. In worldwide ... (see full label)
Indications
- Adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic...
- Conversion to monotherapy in adults (aged 16 years and older) with partial-onset...
- Maintenance treatment of bipolar I disorder to delay mood episodes
Adult dosing
- epilepsy adjunctive valproate: dose: 25; unit: mg; route: PO; interval: every other day for weeks 1 and 2; fixed: true; labelExcerpt: Weeks 1 and 2 25 mg every other day
- bipolar maintenance standard: dose: 200; unit: mg; route: PO; interval: daily maintenance; fixed: true; labelExcerpt: The target dose of lamotrigine is 200 mg/day
Pediatric dosing
- epilepsy adjunctive valproate: dose: 0.15; unit: mg/kg/day; route: PO; interval: weeks 1 and 2; weightBased: false; pedNote: No label-stated per-dose maximum verified; weight-based calculation disabled. Consult pharmacy/current label.; labelExcerpt: Weeks 1 and 2 0.15 mg/kg/day in 1 or 2 divided doses, rounded down to the nearest whole tablet
Renal adjustment
- Reduced maintenance doses may be effective for patients with significant renal impairment. Label: "Reduced maintenance doses may be effective for patients with significant renal impairment [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ]."
Hepatic adjustment
- No dosage adjustment needed for mild impairment. Reduce initial, escalation, and maintenance doses by approximately 25% for moderate/severe impairment without ascites, and by 50% for severe impairment with ascites.
Contraindications
- Hypersensitivity to the drug or its ingredients
Clinical pearls
- Serious, life-threatening skin rashes (including SJS/TEN) can occur; discontinue immediately at first sign of rash unless clearly not drug-related.
- Risk of rash is increased by exceeding recommended initial dose or escalation rate, and by coadministration with valproate.
- Patients should be advised to visually inspect tablets to avoid medication errors due to package/name confusion.
- Maintenance doses may need adjustment when starting or stopping estrogen-containing oral contraceptives.
Source and review
- DailyMed label (lamotrigine), Set ID 20e156df-a2b6-4710-b526-0419cd17dd33, effective 2026-09-04. Last reviewed: 2026-11-11
RotationRx · Drugs · Scores · Protocols · Diagnoses · Specialties